Summary: In 192 adults with type 2 diabetes at a single ambulatory clinic, a multidisciplinary multifactorial programme combining medication optimisation and lifestyle support produced a modest but statistically significant HbA1c reduction (mean difference -0.36%, 95% CI -0.54 to -0.19, P<0.01) and a higher adjusted eGFR (3.93 mL/min/1.73m2, 95% CI 1.27 to 6.58, P<0.01) versus standard care over about 12 months, with these surrogate gains achieved despite lower diabetes medication use.
PICO Summary
| Element | Detail |
|---|---|
| Population | 192 Emirati adults with type 2 diabetes attending one ambulatory clinic (single-centre RCT, United Arab Emirates); mean follow-up 11.9 months. |
| Intervention | Multifactorial intervention by a multidisciplinary team (medication optimisation plus diet, exercise and adherence support) delivered at 3, 6 and 9 month visits. |
| Comparison | Standard routine care over the same period. |
| Outcome | HbA1c mean difference -0.36% (95% CI -0.54 to -0.19, P<0.01); adjusted eGFR difference 3.93 mL/min/1.73m2 (95% CI 1.27 to 6.58, P<0.01); LDL-C mean difference -0.14 mmol/L (95% CI -0.27 to 0.001, P<0.03). HbA1c <7% reached in 40.4% (intervention) versus 31.6% (control); blood pressure target attainment rose from 38.3% to 51.1% (intervention) versus 34.7% to 36.7% (control). No hard cardiovascular event reduction or ARR/NNT was reported. Benefits occurred despite reduced diabetes medication use. |
Multifactorial care in type 2 diabetes
RCT · type 2 diabetes · 12 months
Multidisciplinary multifactorial care gave a modest but significant HbA1c reduction and higher eGFR versus standard care over 12 months, achieved despite lower diabetes medication use. Surrogate endpoints only, no hard cardiovascular outcomes.
Expert Commentary
This single-centre randomised trial supports an intuitive proposition: structured multidisciplinary care, layering lifestyle support onto medication optimisation, can tighten metabolic control in type 2 diabetes. The verdict should be read as a positive but modest signal on surrogate endpoints rather than proof of clinical benefit. The HbA1c mean difference of -0.36% is statistically significant yet small, and the improvements in eGFR and LDL-C, while reaching significance, are of uncertain durability over a follow-up of roughly twelve months. The most encouraging detail is that glycaemic and renal gains were obtained alongside reduced diabetes medication use, which is consistent with a genuine lifestyle contribution. The principal limitation is that this was a single-clinic study of 192 participants reporting biochemical surrogates, with no demonstrated reduction in cardiovascular events and no absolute risk reduction or number needed to treat to anchor the findings; a behavioural multidisciplinary intervention also cannot be truly blinded, so performance and ascertainment bias cannot be excluded. Can I use this with my patients? Yes, for motivated adults with suboptimally controlled type 2 diabetes who can access coordinated dietetic, pharmacy and physician input, the approach is reasonable and low-risk. I would welcome a larger multicentre trial powered for hard outcomes before treating these surrogate gains as established efficacy.
References
El-Deyarbi M, Ahmed L, King J, Adi ZS, Al Juboori A, Mansour NA, et al. Impact of multifactorial interventions with medication and lifestyle optimization on patients with type 2 diabetes: A randomised controlled trial. PLoS One. 2025;20(7):e0327211. doi:10.1371/journal.pone.0327211